Evidence map›Paper›PMID 33968431›Full record

ArticleJournal of gastrointestinal oncology2021

Conversion surgery in patients with pancreatic cancer and peritoneal metastasis.

Suguru Yamada, Tsutomu Fujii, Tomohisa Yamamoto, Hideki Takami, Isaku Yoshioka, So Yamaki, Fuminori Sonohara, Kazuto Shibuya, Fuyuhiko Motoi, Satoshi Hirano and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. [Advances in Surgical Treatment Following Conversion Therapy for Pancreatic Cancer].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Suguru YamadaNagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan.
Tsutomu FujiiDepartment of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Tomohisa YamamotoDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Hideki TakamiNagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan.
Isaku YoshiokaDepartment of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
So YamakiDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Fuminori SonoharaNagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan.
Kazuto ShibuyaDepartment of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
Fuyuhiko MotoiDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Satoshi HiranoDepartment of Surgery, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yoshiak MurakamiDepartment of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hitoshi InoueDepartment of HBP and Breast Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Masamichi HayashiNagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan.
Daisuke HashimotoDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Kenta MurotaniBiostatistics Centre, Graduate School of Medicine, Kurume University, Fukuoka, Japan.
Joji KitayamaDepartment of Gastrointestinal Surgery, Jichi Medical University, Tochigi, Japan.
Hideki IshikawaDepartment of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yasuhiro KoderaNagoya University Graduate School of Medicine, Gastroenterological Surgery, Nagoya, Japan.
Mitsugu SekimotoDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Sohei SatoiDepartment of Surgery, Kansai Medical University, Hirakata, Japan.
Kansai Medical University · JPNagoya University · JPUniversity of Toyama · JPEhime University · JPHiroshima University · JPHokkaido University · JPJichi Medical University · JPKurume University · JPKyoto Prefectural University of Medicine · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies globally. We have previously explored the clinical efficacy of intraperitoneal (IP) paclitaxel therapy for patients with PDAC and peritoneal metastasis, which demonstrated favourable response and disease control rates. However, the real implications of conversion surgery after IP therapy remain unclear.

methodsWe conducted two multicenter clinical trials of IP therapy with paclitaxel in patients with PDAC and peritoneal metastasis. We focused on patients who underwent conversion surgery and investigated the long-term outcomes, particularly, initial recurrence patterns and long-term survival.

resultsSeventy-nine patients with PDAC and peritoneal metastasis were treated, and 33 (41.8%) patients received SP (intravenous IP paclitaxel with S-1) and 46 (58.3%) were administered GAP (intravenous gemcitabine + nab-paclitaxel combined with IP paclitaxel) combination therapy. Of the 79 patients, 16 (20.3%) underwent conversion surgery. The median time to surgery was 9.0 (range, 4.1-13.0) months after the initiation of chemotherapy. Finally, 13 (81.3%) patients underwent R0 resection. Evans grade was IIA in nine patients, IIB in four patients, III in two patients, and IV in one patient. The median overall survival time in patients who underwent conversion surgery was 32.5 (range, 13.5-66.9) months. Twelve (75.0%) patients were found to have experienced recurrence after conversion surgery. Especially, peritoneal recurrence was observed in 50% of patients as the initial recurrence pattern. The median recurrence-free survival time was 9.2 (range, 5.1-32.8) months, and three patients have survived without recurrence to date.

conclusionsOur IP therapy displays promising clinical efficacy with acceptable tolerability in patients with PDAC and peritoneal metastasis. Although we could observe some super-responders in the cohort, further improvements in IP therapy are warranted.

Indexed as

Conversion surgeryintraperitoneal therapy (IP therapy)pancreatic cancerperitoneal metastasis

Identifiers

PMID33968431
PMCPMC8100706
OpenAlexW3047822352

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.